Adenosine A₃ receptor as a novel therapeutic target to reduce secondary events and improve neurocognitive functions following traumatic brain injury

Susan A. Farr, Salvatore Cuzzocrea, Emanuela Esposito, Michela Campolo, Michael L. Niehoff, Timothy M. Doyle, and Daniela Salvemini

Abstract

**Background:** Traumatic brain injury (TBI) is a common pathological condition that presently lacks a specific pharmacological treatment. Adenosine levels rise following TBI, which is thought to be neuroprotective against secondary brain injury. Evidence from stroke and inflammatory disease models suggests that adenosine signaling through the G protein-coupled A₃ adenosine receptor (A₃AR) can provide antiinflammatory and neuroprotective effects. However, the role of A₃AR in TBI has not been investigated.

**Methods:** Using the selective A₃AR agonist, MRS5980, we evaluated the effects of A₃AR activation on the pathological outcomes and cognitive function in CD1 male mouse models of TBI.

**Results:** When measured 24 h after controlled cortical impact (CCI) TBI, male mice treated with intraperitoneal injections of MRS5980 (1 mg/kg) had reduced secondary tissue injury and brain infarction than vehicle-treated mice with TBI. These effects were associated with attenuated neuroinflammation marked by reduced activation of nuclear factor of kappa light polypeptide gene enhancer in B cells (NFkB) and MAPK (p38 and extracellular signal-regulated kinase (ERK)) pathways and downstream NOD-like receptor pyrin domain-containing 3 inflammasome activation. MRS5980 also attenuated TBI-induced CD4⁺ and CD8⁺ T cell influx. Moreover, when measured 4–5 weeks after closed head weight-drop TBI, male mice treated with MRS5980 (1 mg/kg) performed significantly better in novel object-placement retention tests (NOPRT) and T maze trials than untreated mice with TBI without altered locomotor activity or increased anxiety.

**Conclusion:** Our results provide support for the beneficial effects of small molecule A₃AR agonists to mitigate secondary tissue injury and cognitive impairment following TBI.

**Keywords:** Traumatic brain injury, A₃AR, Neuroinflammation, Cognitive impairment, NLRP3
Introduction
Traumatic brain injury (TBI) is a common pathological condition presently lacking a specific pharmacological treatment approved by the Food and Drug Administration [1]. TBI results in long-term physical and cognitive deficits arising from primary and secondary injuries. The primary injury starts at the moment of TBI impact and is characterized by the disruption of blood brain barrier and blood vessels that contribute to the formation of brain edema [2, 3]. This triggers a secondary injury cascade that includes the activation of brain-resident astrocytes and microglia and enrollment of peripheral immune cells into the brain. As a result, these immune components may promote cell death during the early phase after TBI impact and contribute to subsequent neurological impairments during the later stages [2, 4–6]. Therefore, targeting secondary events following TBI could be a promising strategy for the development of novel therapy [7].

Adenosine levels rise in the cerebrospinal fluid and interstitial space 1 h after TBI in animals and humans [8, 9]. Further adenosine release occurs during periods of mismatched cerebral blood flow and cerebral metabolic rate of oxygen consumption in TBI patients [10]. Upon release, adenosine can bind to one of four G protein-coupled receptor (GPCR) subtypes: A1AR, A2AAR, A2BAR, and A3AR [11].

Our knowledge of the role of adenosine signaling during TBI has been limited to its action at A1AR and A2AAR. In TBI models, A1AR signaling has been shown to be neuroprotective [12] and reduce the severity of secondary injury [13]. In contrast, A2AAR activation is detrimental and increases TBI-induced cognitive impairment [14]. A2AAR inhibition was found to provide anti-inflammatory and neuroprotective effects that corresponded with improved histopathological outcomes over the course of the study [15] and antagonism of A2AAR signaling with caffeine after TBI reduced secondary brain injury and improved cognitive function [16, 17]. Collectively, these data point to a beneficial role for adenosine signaling during TBI and suggest adenosine signaling may be a good pharmacological target for treating TBI. However, targeting A1AR and A2AAR as a therapeutic approach to reduce secondary injury and loss of cognitive function following TBI have been limited. Systemic administration of A1AR agonists can produce serious adverse cardiovascular effects [18]. The use of caffeine has been linked to increased acute granulocytosis, edema, and disruption of the blood–brain barrier in animals [17] and chronic administration can reduce the recovery of motor function in patients [16].

The role of A3AR in TBI is not known. A3AR signaling has demonstrated antiinflammatory effects in models of autoimmune inflammatory diseases and chronic neuropathic pain [19, 20] as well as anticancer and cardioprotective properties [21]. Accordingly, orally bioavailable small molecule, receptor subtype-selective A3AR agonists, IB-MECA (CF101, picladenoson) and Cl-IB-MECA (CF102, namodenosin) have been developed and advanced to Phase II/III for autoimmune inflammatory conditions and cancer with good safety profiles [22–24]. In the brain, A3AR is generally expressed at low levels [11, 21, 25], yet immunohistochemical and radioligand binding studies have demonstrated A3AR expression clusters in various brain regions, including the hippocampus and cortex [26]. Studies in animal stroke models found improved ischemic outcome by reducing infarct volume and inflammatory cell infiltration with A3AR agonist treatment [27, 28]. In contrast, A3AR−/− knockout mice were found to be more susceptible to hypoxia-induced hippocampal nerve death and exhibited increased cognitive decline than wild-type mice [29]. Given the apparent anti-neuroinflammatory and neuroprotective effects associated with A3AR signaling in the brain, we investigated whether A3AR activation improves pathological outcomes of secondary injury by attenuating inflammation and preserves cognitive function in animal models of TBI. Here, we used the highly-selective A3AR agonist MRS5980 (> 10,000 fold selectivity versus A1AR or A2AAR) [30, 31] that has been reported to only bind the A3AR in a full GPCRome and kinome screen [32] and whose effects are fully blocked by the A3AR antagonist MRS1523 [33].

Materials and methods
Materials
MRS5980 ((1S,2R,3S,4R,5S)-4-(2-((5-chlorothiophen-2-yl)ethyl)yl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide, gift of Kenneth A. Jacobson, NIDDK, National Institutes of Health) was prepared as described recently [34]. All other chemicals were purchased from the highest commercial grade available. All stock solutions were prepared in non-pyrogenic saline (0.9% NaCl, Baxter, Milan, Italy) or dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, USA).

Experiment animals
Male CD1 mice were used at 10 and 12 weeks of age (25 to 30 g) from Envigo (Italy) for controlled cortical impact TBI studies (Study 1) or from Charles River (Wilmington, MA) for closed-head weight drop TBI studies (Study 2). Mice were housed in individual cages (five per cage) and maintained under a 12:12 hour light/dark cycle at 21 ± 1 °C and 50 ± 5% humidity. Regular laboratory diet (Study 1) or PMI Nutrition LabDiet 5001 (Study 2) and tap water were available ad libitum.
Study design
All animals were sex-, age- and weight-matched and experimentally naïve prior to head injury. To assure reproducibility, data were compiled from two to three experiments with equal number of animals in each group and behavioral experiments and corresponding biochemical assays were started and performed on different days with experimenters blinded to treatment conditions.

Study 1: controlled cortical impact traumatic brain injury
Mice were randomly allocated into the following groups: (1) sham: mice were subjected to equal surgical procedures except for TBI and were kept under anesthesia for the duration of the surgery (n = 25); (2) TBI: mice were subjected to brain injury then administered an intraperitoneal (i.p.) injection of vehicle (saline at 5% dimethyl sulfoxide (DMSO)) 1 h and 4 h after trauma (n = 25) and (3) TBI + MRS5980: mice were subjected to brain injury then administered an i.p. injection of MRS5980 (1 mg/kg, i.p.) 1 h and 4 h after trauma (n = 25).

Traumatic brain injury was induced in mice by a controlled cortical impactor (CCI) as previously described [35, 36]. Briefly, a craniotomy of the right hemisphere encompassing the bregma and lambda between the sagittal suture and the coronal ridge was performed with a micro motor hand piece and drill (UGO Basile SRL, Comerio Varese, Italy). The resulting bone flap was removed and the cranial aperture was enlarged with cranial rongeurs (New Adalat Garh, Roras Road, Pakistan). A cortical contusion was made using the controlled stereotaxic impactor (Leica, Milan, Italy) on the exposed cortex (tip diameter: 4 mm; cortical contusion depth: 3 mm; impact velocity: 1.5 m/s). This generates brain injury of moderate severity [37]. Immediately after injury, the skin incision was secure with nylon sutures, and 2% lidocaine jelly in the lesion was used to reduce pain. No seizures or deaths were observed in any of these mice. All groups were sacrificed 24 h post-injury for histopathological and biochemical analyses.

Study 2: closed head weight-drop traumatic brain injury
Mice were randomly assigned to the following groups: (1) sham: mice were anesthetized with isoflurane and placed in the apparatus but not subjected to head injury. Mice were administered i.p. injections of vehicle (saline with 5% DMSO) after 1 h every 2 days for the duration of the study (n = 11); (2) TBI + vehicle: mice were anesthetized with isoflurane and place in the apparatus and subjected brain injury. Mice were administered i.p. injections of vehicle after 1 h and every 2 days for the duration of the study (n = 11); and (3) TBI + MRS5980: mice were anesthetized with isoflurane and placed in the apparatus and subjected to head injury. Mice were administered i.p. injections of MRS5980 (1 mg/kg) after 1 h and every 2 days for the duration of the study (n = 11).

Traumatic brain injury was induced in mice using the closed-head concussive method [38]. Briefly, mice were anesthetized with 2–4% isoflurane (confirmed by the loss of corneal reflex and toe pinch reflex). Then, the animal’s head was placed an immobilization sponge board and positioned under a device consisting of a Plexiglas tube (inner diameter 13 mm) placed vertically over the animal’s head. A 30-g acrylic weight was dropped down the Plexiglas tube from an 80 cm height, striking the head in area encompassing right of the central suture, behind bregma and in front of lambda on the parietal lobe. Following this procedure, the animal’s respiration, heart rate and righting reflex were monitored to ensure recovery. Mice with abnormal reflexes or exhibited abnormal ambulation 1 h after trauma were eliminated from study and euthanized by CO₂ asphyxiation. No signs of seizures were observed in any of the mice. Materials for the apparatus were made by Interstate Plastics, Incorporated, Sacramento, CA.

Histopathological quantification of brain injury
The mouse brains were harvested 24 h after CCI, fixed in 10% (w/v) buffered formaldehyde and paraffin-embedded. Coronal sections (7 μm) from the perilesional brain area of each animal were deparaffinized with a decreasing concentrations of xylene and alcohol, then stained with hematoxylin and eosin. All sections were analyzed by using an Axiovision Zeiss microscope (Milan, Italy). Histopathological changes of the gray matter were blindly scored using a 5-point scale: 0, no lesion observed; 1, gray matter contained 1 to 5 eosinophilic neurons; 2, gray matter contained 5 to 10 eosinophilic neurons; 3, gray matter contained more than 10 eosinophilic neurons; 4, small infarction—less than one third of the gray matter area; 5, large infarction—more than half of the gray matter area [39, 40]. The scores from all the brain sections were averaged for a final score for an individual mouse.

Quantification of infarct volume
The mouse brains were harvested 24 h after CCI and cut into 5 coronal slices of 2 mm thickness by using a McIlwain tissue chopper (Campden instruments LTD). Slices were incubated in 2,3,5-triphenyltetrazolium chloride (TTC; 2%) at 37°C for 30 min and immersion fixed in 10% buffered formalin solution. Infarcted area and volume were calculated as previously described [41] using digital images (Canon 4X, Canon Inc., China) and ImageJ software [42]. To account for brain edema, the infarct areas were corrected by subtracting the area of the contralateral hemisphere area from the ipsilateral
hemisphere [43]. The corrected total infarct volume was estimated by summing the infarct area in every slice and multiplying it by slice thickness (2 mm).

**Western blot analysis**

Cytosolic and nuclear extracts were prepared from fresh brain sections 24 h after CCI as previously described [35]. The expressions of cleaved caspase 1 p20, NLRP3, IkBa, p-p38 and p-ERK 1/2 was quantitated using cytosolic fractions while NFkB was detected in nuclear fraction. The Western blot membranes were probed with antibodies for nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha (IkBa; 1:500; Santa Cruz Biotechnology), nuclear factor of kappa light polypeptide gene enhancer in B cells (NFkB; 1:1000; BD Transduction Laboratories), p-p38 (1:500; Santa Cruz Biotechnology; sc-17852-R), total p38 (1:500; Santa Cruz Biotechnology, Santa Cruz CA, USA), phophorylated extracellular signal-regulated kinases (p-ERK 1/2; 1:500; Santa Cruz Biotechnology), total ERK 1/2 (1:500; Santa Cruz Biotechnology), cleaved caspase 1 p20 (1:500; Santa Cruz Biotechnology; sc-1597) or NLRP3 (1:500; Santa Cruz Biotechnology; sc-66846) at 4°C overnight in 1× phosphate-buffered saline (PBS), 5% non-fat dried milk and 0.1% Tween-20. Membranes were incubated with peroxidase-conjugated bovine anti-rabbit IgG secondary antibody or peroxidase-conjugated goat anti-mouse IgG (1:2000; Jackson Immunoresearch, West Grove, PA, USA) for 1 h at room temperature. Equal protein loading was assessed by incubating the blots in the presence of antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:5000; Santa Cruz Biotechnology) for cytosolic proteins and lamin A/C (1:1000; Santa Cruz Biotechnology) for nuclear proteins. The signals were visualized with enhanced chemiluminescence detection system reagent according to the manufacturer’s instructions (Super Signal West Pico Chemiluminescent Substrate, Pierce Thermo Scientific, Rockford, IL, USA). Relative expression of bands were calculated by densitometry using Bio-Rad ChemiDoc™ XRS + software and Image Quant TL, v2003. The expression levels of target proteins were standardized to GAPDH and/or Lamin A/C levels. Phosphorylated proteins were standardized to their total protein values.

**Immunofluorescence staining**

Tissue segments containing the lesion (1 cm on each side of the lesion) were fixed in 10% (w/v) buffered formaldehyde 24 h after CCI and paraffin embedded as previously described [36]. After deparaffinization and rehydration, the tissue was boiled in 0.1 M citrate buffer for 1 min and blocked in 2% (v/v) normal goat serum in PBS for 20 min. Sections were incubated with mouse monoclonal with polyclonal mouse anti-CD4 (1:100, v/v, Santa Cruz Biotechnology, Dallas, TX, USA) or anti-CD8 (1:100, Santa Cruz Biotechnology, Dallas, TX, USA) antibodies in a humidified chamber overnight at 37 °C. Sections were washed with 1× PBS and incubated with secondary antibody FITC-conjugated anti-mouse Alexa Fluor-488 antibody (1:2000 v/v Molecular Probes, UK) for 3 h at 37 °C. Sections were washed and nuclei were stained with 2 μg/ml 4′-6-diamidino-2-phenylindole (DAPI; Hoechst, Frankfurt, Germany) in 1× PBS. Sections were observed and photographed at ×100 magnification using a Leica DM2000 microscope (Leica). All images were digitalized at a resolution of 8 bits into an array of 2560 × 1920 pixels. Optical sections of fluorescence specimens were obtained using a helium-neon laser (543 nm), a UV laser (361–365 nm) and an argon laser (458 nm) at a 1-min, 2-s scanning speed with up to 8 averages; 1.5 μm sections were obtained using a pinhole of 250. Contrast and brightness were established by examining the most brightly labeled pixels and applying settings that allowed clear visualization of structural details while keeping the highest pixel intensities close to 200. The same settings were used for all images obtained from the other samples that had been processed in parallel. Digital images were cropped and figure montages prepared using Adobe Photoshop CS6 (Adobe Systems; Palo Alto, CA, USA).

**Cognitive behavioral tests**

All mice in Study 2 were tested 1 week and again at 4 weeks after sham or closed head weight-drop traumatic brain injury.

**Novel Object Recognition Place recognition Test (NORPT)**

Novel object-place recognition test (NORPT) is a memory task that involves the hippocampus where the animal is tested on whether it retains the memory of an object it was exposed to 24 h prior to testing [44]. This test exploits the tendency of mice to spend more time exploring new, novel objects than familiar objects. Thus, the greater the retention/memory of the familiar object, the more time they will spend with the new object.

NORPT trials for mice 1 week after trauma began for 3 days prior to test day where they were allowed to habituate to the test arena (25 cm (length) × 25 cm (width) × 50 cm (height) for 5 min/day. On day 4, two identical objects were placed in the arena and the mouse was permitted to freely explore the arena for 5 min. The mouse was returned to its home-cage and the arena and the two objects were cleaned with 70% ethanol. The mouse was returned to the open arena 24 h later and one object was replaced by a novel object with different shape in a different location. The mice were allowed to explore for another 5 min. The familiar and novel objects were of
the same material to avoid potential interference of deficits in sense of touch or smell. All sessions were recorded for later analysis. Sniffing, climbing, and touching the objects were regarded as the exploration behavior and exploration times of the familiar and novel object were scored manually by a trained technician blinded to treatment and were validated by a second investigator.

NORPT trials for mice 4 weeks after trauma began the day before test day where they were allowed to explore the two like objects for 5 min. The next day, they were placed back in the arena with one object from the day prior and one new object. The objects for these test sessions were made of different material and different shapes than the test at 1 week post-injury.

Mice that did not explore both objects were not included in the analysis. The discrimination index was calculated as (time with novel-time with familiar object)/total exploration time of both objects. The NORPT was performed during the light phase of the day/night cycle.

**T-Maze training and testing procedures**
The T-maze is a complex memory task involving the hippocampus. Permanent and temporary lesions to 30% of the anterior portion of the hippocampus result in impaired learning and memory during the T maze trials [45]. The T-maze consisted of a black plastic alley with a start box at one end and two goal boxes at the other. The start box was separated from the alley by a plastic guillotine door that prevented movement down the alley until raised at the onset of training. An electrifiable floor of stainless steel rods ran throughout the maze to deliver a mild scrambled foot-shock.

Mice were tested in T-maze starting 4 weeks post-TBI. Mice were not permitted to explore the maze prior to training. A block of training trials began when a mouse was placed into the start box. The guillotine door was raised and a cue buzzer (door-bell type sounded at 55 dB) sounded simultaneously; 5 s later foot-shock (0.35 mA; Coulbourn Instruments scrambled grid floor shocker model E13-08) was applied. The arm of the maze the mouse entered on the first trial was designated “incorrect” and the mild foot-shock was continued until the mouse entered the other goal box, which in all subsequent trials was designated as “correct” for the particular mouse. At the end of each trial, the mouse was returned to its home cage until the next trial (inter-trial interval = 35 s). Retention was tested 1 week later by continuing training until mice reached the criterion of 5 avoidance in 6 consecutive trials. The results were reported as the number of trials to criterion for the retention test.

**Open-field test**
To determine if cognitive test performance was affected by changes in animal activity or anxiety due to trauma or MRS5890 treatment, the mice were placed in an open field 4 weeks after closed head weight-drop traumatic brain injury. The mice were allowed to freely roam an empty circular apparatus (67.5 cm) for 15 min and distance traveled in cm as well as the time spent in the center portion of the open field was recorded on an ANY-maze (San Diego Instruments, CA, USA).

**Elevated plus maze test**
To further assess potential alterations in the levels of activity and anxiety in our mice, we measured their performance in the elevated plus maze during week 4 after closed head weight-drop traumatic brain injury. The apparatus consists of 4 arms perpendicular to each other in the shape of a plus sign, elevated 50 cm above the floor. Each arm is 35.5 cm in length; two opposite arms are open while the other two opposite arms are enclosed, as previously described [38]. The mouse is placed in the central platform facing an enclosed arm and allowing it to freely explore the maze for 5 min. The number of entries into the open and closed arms and the time spent in open arms was recorded by the ANY-maze. Anxiety and activity was indicated by decreased time spent and the number of entries in the open arms. The test arena was wiped with a damp cloth after each trial.

**Statistical analysis**
All values in the figures and text are expressed as mean ± standard error of the mean (SEM) of N number of animals. In those experiments involving histology or immunohistochemistry, the pictures exhibited are representative of at least three experiments performed on different days. Data that did not pass Shapiro-Wilk normality testing were analyzed by Kruskal-Wallis with Dunn’s comparison. All other data were analyzed two-tailed, two-way ANOVA with Bonferroni comparisons or one-way ANOVA followed by a Dunnett’s comparisons. A p value < 0.05 was considered significant.

**Results**
**MRS5980 attenuates gross histopathological changes to cortical tissue following CCI**
Consistent with previous reports [35, 36, 46, 47], the examination of brain sections from mice 24 h after sham injury (Fig. 1a, b, g) or CCI-induced TBI (Fig. 1c, d, g) revealed increased tissue disorganization and white matter alteration in the brain parenchyma of the perilesional area of mice with TBI. Moreover, the degree of brain infarction and necrotic tissue was greater in mice with TBI mice than sham mice (Fig. 2). However, mice
Fig. 1. MRS5980 attenuates gross histopathological changes to cortical tissue following CCI TBI. a–f When compared to the intact brain structure of sham mice (a and higher magnification in b), tissue disorganization and inflammation increased in the penumbra area of the mouse brain sections 24 h after CCI TBI (TBI + Veh; c and higher magnification in d). These histopathological changes were attenuated in mice treated with MRS5980 (1 mg/kg, i.p.) after CCI TBI (e and higher magnification in f). g Histological scores of sagittal brain slices (three slices per animal). ND = not detectable; yellow box indicates region of higher magnification. Data are mean ± SEM of 10 mice/group and analyzed by Kruskal-Wallis \([H(2)- = 24.17, p = 5.63 \times 10^{-6}]\) and Wilcoxon signed-rank test. \(*p < 0.05\) vs. sham and \(\dagger p < 0.05\) vs. TBI + Veh.

Fig. 2. MRS5980 reduces the level of brain infarction following CCI TBI. a In serial coronal brain sections (2 mm thick) from sham group (side of sham surgery indicated by gray arrows), the level of TTC staining (red) was strong and uniformed indicating high metabolic and adequately perfused mouse brain. In contrast, the level of TTC staining in the brains from mice with TBI (side of CCI indicated by yellow arrows) and treated with vehicle (24 h after CCI TBI) was reduced overall and non-uniform, indicating increased brain infarction (white unstained regions). In brains from mice with CCI TBI (side of CCI indicated by yellow arrow) and treated with MRS5980 (1 mg/kg; i.p.), the level of TTC staining was greater and the regions of infarction (white unstained regions) were less than in untreated mice with TBI. b, c Morphometric analyses of infarct area and volume in TTC-stained brain slices. ND = not detectable. Data are individual value (b) or mean ± SEM (c) of 10 mice/group and analyzed by two-tailed, (b) two-way ANOVA \([F(6, 81) = 2908; p = 2.32 \times 10^{-92}, \eta^2_p = 0.995]\) with Bonferroni comparisons or (c) one-way ANOVA \([F(2, 27) = 5006; p = 2.00 \times 10^{-35}, \eta^2 = 0.997]\) with Dunnett’s comparisons. \(*p < 0.05\) vs. sham and \(\dagger p < 0.05\) vs. TBI + Veh.
administered MRS5980 (1 mg/kg; i.p) at 1 h and 4 h after TBI had significantly less brain tissue damage (Fig. 1e, f, g) and lesion volume (Fig. 2) when examined 24 h after trauma.

**MRS5980 attenuates the activation of NFkB and MAPK pathways following CCI**

NFkB [48–50] and MAPK (p38 and ERK) [50–52] signaling pathways have been shown to be activated in perilesional brain tissue in animal models of CCI TBI. Consistent with these reports, we found that TBI resulted in reduced cytoplasmic expression of the endogenous NFkB inhibitor IkBa (Fig. 3a) and increased nuclear translocation of NFkB p65 (Fig. 3b) in the perilesional brain tissue 24 h after injury, indicating the activation of the NFkB pathway. Likewise, we found phosphorylation of p38 (Fig. 3c) and ERK (Fig. 3d) increased following CCI TBI, indicating similar activation of MAPK signaling.

As part of their antiinflammatory mechanism of action, A3AR agonists have been shown to attenuate NFkB and MAPK signaling in number of autoimmune inflammatory disease models [31, 53]. When mice were treated with MRS5980 (1 mg/kg; i.p) 1 h and 4 h after TBI, we found increased cytoplasmic IkBa (Fig. 3a) and reduced nuclear NFkB p65 (Fig. 3b) and phosphorylation of p38 (Fig. 3c) and ERK (Fig. 3d) in the perilesional brain tissue 24 h after injury when compared to mice with TBI and treated with vehicle.

**MRS5980 attenuates NLRP3-inflammasome following CCI**

Inflammatory NFkB [54–56] and MAPK [55, 57] signaling increase the expression of the scaffold protein NOD-like receptor pyrin domain-containing 3 (NLRP3). Following a secondary inflammatory stimulus, NLRP3

---

**Fig. 3** MRS5980 attenuates the activation of Nfkb and MAPKs pathways following CCI TBI. When compared to sham mice, the levels of cytoplasmic IkBa were decreased (a) and the levels of nuclear NFkB p65 (b) and phosphorylated p38 (c) and ERK1/2 (d) increased in brain tissue from mice 24 h after CCI TBI that were treated with vehicle. These events were attenuated in mice with CCI TBI and treated with MRS5980 (1 mg/kg; i.p.; a-d). Uncropped blot images are shown in the supplementary information (Figures S1, S2, S3 and S4). Data are mean ± SEM for 5 mice/group and analyzed by two-tailed, one-way ANOVA with Dunnett’s comparisons [a F(2, 12) = 1098, p = 2.57 × 10−14, η² = 0.995; b F(2, 12) = 1800, p = 1.13 × 10−9, η² = 0.968; c F(2, 12) = 325.5, p = 3.52 × 10−11; η² = 0.992; d F(2, 12) = 325.5, p = 3.52 × 10−11, η² = 0.992]. *p < 0.05 vs. sham and †p < 0.05 vs. TBI + Veh.
forms a complex with the apoptosis-associated speck-like protein containing a CARD (ASC) and procaspase 1 and several NLRP3-ASC-procaspase 1 complexes then oligomerize to form the inflammasome [58]. The formation of the inflammasome stimulates the autocleavage and activation of caspase 1, which is critical for the post translational activation of inflammatory cytokines IL1β and IL18 [58].

NLRP3-inflammasome activation occurs within 24 h following TBI [59] and its inhibition reduces the severity of tissue damage following TBI [60–62]. We have recently reported that A3AR agonist attenuate the activation of NLRP3 during the neuroinflammatory events in the spinal cord associated with neuropathic pain [63]. In our CCI TBI mouse models, we found increased expression of NLRP3 (Fig. 4a) and cleaved caspase 1 (p20) (Fig. 4b) in the perilesional region of the cortical brain in mice 24 h after injury. This was attenuated in mice with CCI TBI that were treated with MRS5980 (1 mg/kg; i.p.) (Fig. 4).

MRS5980 attenuates CD4+ and CD8+ T cell infiltration following CCI

The infiltration of CD4+ T helper cells have been reported to increase following TBI [36] and contribute to the severity of tissue injury [64, 65]. Consistent with these previous findings, immunofluorescence evaluation of cortical slices from our mice 24 h after CCI revealed increased levels of CD4+ and CD8+ staining in the perilesional region compared to sham mice (Fig. 5).

Administration of MRS5980 (1 mg/kg; i.p.) markedly reduced CD4+ and CD8+ T cell staining (Fig. 5).

MRS5980 prevents the development of cognitive impairment after closed head weight-drop TBI

We next tested whether the beneficial effects of MRS5980 on the underlying TBI pathology and signaling mechanisms translated into protection against cognitive impairment following TBI. Here, we used the closed head weight-drop model of TBI to model the more common closed head TBI seen in the clinic [66]. This model has pathological and neurochemical features similar to those of the CCI model [67, 68]. When memory function was tested 1 week after closed head weight-drop TBI, mice with TBI performed equally well compared to sham mice during NORPT trials (Fig. 6a). However, by 4 weeks, mice with TBI spent significantly less time with the novel objects than the sham mice, indicating a loss of recognition memory of the conditioned object (Fig. 6b). Administration of MRS5980 (1 mg/kg; i.p.) 1 h and every 2 days after trauma attenuated this reduction in recognition memory in mice 4 weeks after TBI (Fig. 6b). MRS5980 had no effect on recognition memory 1 week after TBI (Fig. 6a).

We further explored the effects of MRS5980 on memory and learning using the T maze test. Here, testing 4 weeks after closed head weight-drop TBI revealed that mice with TBI required significantly more trials to achieve 5 avoidances in 6 consecutive trials than sham mice (Fig. 6c). However, those with TBI that were...
treated with MRS5980 (1 mg/kg; i.p.) 1 h and every 2 days after trauma required fewer trials than mice with TBI (Fig. 6c).

Mice with TBI and those treated with MRS5980 (1 mg/kg; i.p.) 1 h and every 2 days after trauma did not exhibit significant differences in the number of entries (Fig. 7a) or time spent on the open arms (Fig. 7b) of an elevated plus maze than sham mice indicating no differences in anxiety. In the open field, mice with TBI and treated with vehicle showed a modest increase in the time spent in the center of an open field than mice in the sham group (Fig. 7c). However, mice with TBI and treated with MRS5980 were not significantly different than sham mice or vehicle-treated mice with TBI (Fig. 7c), indicating that the difference in open field performance was minor and did not impede the ability of the animals to perform other tasks in our behavioral tests. Moreover, there were no significant differences between

![Fig. 5 MRS5980 attenuates CD4+ and CD8+ T cell infiltration following controlled cortical impact TBI. When compared to the number of CD4+ (a, green) and CD8+ (e, green) T cells in the brain tissue sham mice, the number of CD4+ (b) and CD8+ (f) T cells increased in the brain tissue of mice measured 24 h after CCI and treatment with vehicle. MRS5980 (1 mg/kg; i.p.) attenuated the increase in CD4+ (c) and CD8+ (g) T cells in mice with TBI. Quantitation of CD4+ (d) and CD8+ (h) T cell infiltration measured from three brain slices for each mouse. Yellow arrows = co-localization between CD4 or CD8 (green) and DAPI (blue). All images were digitalized at a resolution of 8 bits into an array of 2048 x 2048 pixels. Bar = 20 μm. Data are mean ± SEM for 10 mice/group and analyzed by two-tailed, one-way ANOVA with Bonferroni comparisons (d: F(2, 27) = 108.0, p = 1.31 x 10^-13, η² = 0.889 and h: F(2, 15) = 53.14, p = 1.56 x 10^-7, η² = 0.876). *p < 0.05 vs. sham and †p < 0.05 vs. TBI + Veh.](image)

![Fig. 6 MRS5980 prevents cognitive impairment by 4 weeks after closed head weight-drop TBI. a When compared to sham (n = 9), there were no differences in the ability of mice 1 week after TBI and vehicle treatment (n = 10) to discriminate between conditioned and novel objects or their placement. MRS5980 (1 mg/kg; i.p.; n = 9) had no effects on the outcome of NOPRT trials (F(2, 26) = 1.092, p = 0.351, η² = 0.077). Animals from the sham (n = 2), TBI + Veh (n = 1) and TBI + MRS5980 (n = 1) groups were excluded because of failure to explore both objects. b In contrast, mice with TBI and treated with vehicle (n = 9) exhibited increased impairment in recognizing the original object from novel objects or their placement compared to sham (n = 9) when tested 4 weeks after TBI. MRS5980 (1 mg/kg; i.p.; n = 9) attenuated this impairment in mice with TBI (F(2, 26) = 8.976, p = 0.00123, η² = 0.428). Additional animals from the TBI + Veh (n = 1) and TBI + MRS5980 (n = 1) were excluded because of failure to explore both objects. c When compared to sham mice (n = 11), the number of trials need to achieve 5 avoidances in 6 consecutive trials in the T maze increased in mice 4–5 weeks after TBI (n = 11). Mice with TBI and treated with MRS5980 (1 mg/kg; i.p.; n = 10) required fewer T maze trials to achieve learning and memory tasks than untreated mice with TBI (H(2) = 13.58, p = 0.00113). One animal from the TBI + MRS5980 was excluded because it would not perform the task. Data are mean ± SD for n mice/group and analyzed by a, b two-tailed, one-way ANOVA with Bonferroni comparisons or c Kruskal-Wallis with Dunn’s comparisons. *p < 0.05 vs. sham and †p < 0.05 vs. TBI + Veh.](image)
groups in the total distance traveled in the open field (Fig. 7d). This suggests the behavioral observed changes with TBI or with MRS5980 treatment following TBI were not associated alterations in locomotor activity or increased anxiety.

**Discussion**

TBI-induced disability is one of the most pressing health crisis in our society [69, 70]. The Centers for Disease Control and Prevention estimates there are over 2.5 million emergency room visits for TBI each year [66] and an estimated 3–5 million people in the US live with a TBI-related disability [66]. Cognitive impairment is a serious outcome following a TBI [71] that impacts an individual’s quality of life and livelihood [70]. In humans, TBI-related deficits are now thought to be long-term in close to 50% of individuals subjected to a TBI [69]. Impairments several weeks post-TBI can be detected in both mild and severe TBI [72]. Pharmacological interventions for treating TBI are limited.

Our findings now demonstrate that systemic post-TBI administration of MRS5980 protected mice from developing memory impairment as measured by two hippocampal tasks (T-maze and novel object recognition impairment) without altering activity or anxiety levels. Since MRS5980 is > 10,000 times more selective for A3AR than for A1AR; our findings establish that A3AR signaling is beneficial in TBI. The degree and duration of cognitive impairment following TBI is linked to the extent of neurodegeneration caused by the initial insult and secondary injury neuronal death [73]. In an animal stroke model, repeated administration of A3AR agonist, IB-MECA, after ischemia was reported to improve cerebral blood flow [74], reduce gliosis and nitric oxide production in the hippocampus and prevent the loss of hippocampal neurons [75]. We now find that the beneficial effects of stimulating A3AR signaling on preserving cognitive function following TBI corresponded with mitigation of secondary injury and ischemia in the surrounding brain tissue, supporting the neuroprotective effects of A3AR agonists. In our model of CCI TBI, we chose the TTC staining method because it is more rapid than conventional histological assessments and permits a more accurate delineation of injured tissue destined to
undergo cell death or degeneration. However, this method is limited in revealing selective neuronal necrosis or other histopathological changes. Future studies investigating the mechanisms engaged by A3AR agonists on TBI pathology will have to address how they impact these finer histopathological changes.

Neuronal cell death during the secondary phase of injury is brought on by complex interactions between increased neuroinflammation and oxidative stress, excessive glutamatergic neurotransmission and alterations in blood-brain barrier integrity and cerebral perfusion pressure regulation that lead to edema and ischemia [76]. Tissues damaged during the initial insult release a milieu of signaling molecules, including damage associated molecular patterns (DAMPs) [2, 7] and adenosine triphosphate [7]. DAMPs recognized by toll-like receptors (TLRs) located on glial cells trigger inflammatory cascades result in the production of inflammatory cytokines and chemokines [77] that, in turn, promote oxidative stress [78], enhance neuronal glutamatergic signaling [79] and affect cerebral perfusion pressure [80]. The inflammatory interleukin (IL), IL-1β, is perhaps the most studied cytokine in TBI and found to be elevated with the first hours following TBI [2, 81]. IL-1β transcription is induced by DAMP-stimulation of toll-like receptors in microglia during TBI and requires post-translation processing by caspase 1 activated by inflammasomes, such as NLRP3 [58]. The levels of NLRP3 inflammasome components and IL-1β are elevated in the cerebrospinal fluid of TBI patients [82]. Moreover, adenosine triphosphate levels rise following TBI [83] and can act as the secondary trigger for inflammasome oligomerization by binding the adenosine triphosphate-gated P2X receptor cation channel subtype 7 (P2X7) [58, 83]. Inhibition of P2X7 following TBI prevents IL-1β expression, glial activation and neuronal cell death [84]. The effects of IL-1β in brain injury have also been linked to promotion granulocytosis that can drive neuronal cell death [83], induction glutamateric neurotoxicity [85], and reduction in cerebral blood flow to exacerbate brain infarction [80]. The elimination of IL-1β signaling in IL-1 receptor (IL1r) knockout mice has been shown to significantly improve cognitive function following TBI ([81]. Here, in our CCI model, we found systemic administration of MRS5980 attenuated NLRP3 expression, as well as the Nfkb and MAPK regulatory pathways, and caspase 1 activation suggesting that the beneficial effects of A3AR activation on cognitive function and tissue injury is related to the prevention of adverse NLRP3-IL-1β signaling. These actions are consistent with our previously reported finding of the effects of A3AR in the CNS in neuropathic pain models where we found A3AR agonists blocked NLRP3 expression and activation [63] and reduced IL-1β expression in the spinal cord [63, 86]. In our neuropathic pain models, A3AR mitigation of NLRP3-dependent IL-1β in spinal cord was associated with increased IL-10 [63, 86]. In TBI models, IL-10 not only attenuates neuroinflammation by reducing inflammatory cytokine production, but also was found be neuroprotective by increasing cerebral blood flow and reducing brain infarction [87].

Although A1AR and A2AAR expression is greater than A3AR in the brain [11, 21, 25], the rapid rise in extracellular adenosine shortly following TBI is likely to engage A1AR, A2AAR, and A3AR to provide acute modulation of the neuroinflammation events provoked by the primary tissue injury. However, these levels appear to be transient with only a short burst of adenosine release when cerebral blood flow does not match the oxygen consumption within the site of injury. The duration of these episodic adenosine releases may be shortened by derangements in the metabolism of extracellular adenosine following TBI [88]. Regulation of extracellular adenosine is largely driven by the intracellular adenosine kinase (ADK), which converts intracellular adenosine to adenosine monophosphate [89]. Increased adenosine kinase activity, such as that seen under pathological conditions, depletes intracellular adenosine and draws extracellular adenosine down its gradient through passive channels [89]. Increased expression of ADK in astrocytes following penetrating (blade-induced) TBI has been found associated with the development of astrogliosis-associated neuronal death; knocking down ADK in astrocytes reduced their proinflammatory phenotype [90]. Moreover, recent studies show that neural stem cell proliferation following controlled cortical impact TBI was impaired in mice overexpressing ADK; whereas its pharmacological inhibition promoted neural stem cell proliferation following TBI [91]. Extracellular adenosine levels are further influenced by the conversion of extracellular ATP to adenosine by ectonucleotidases [92, 93]. In addition to increased adenosine release after TBI, there is release of ATP from the primary injury site that triggers neuroinflammatory responses [83], such as activating microglia [94] and triggering P2X7R-mediated inflammation [84]. However, in penetrative (cortical stab) TBI models, adenosine monophosphate hydrolysis (CD73 activity) was found impaired in cortical regions [95, 96] and the hippocampus [96]. Collectively, the events would lead to short durations of released adenosine and low adenosine level between these episodes, which at its best may only be sufficient to engage A1AR and A2AAR, thus creating deficiencies in long-term beneficial endogenous A3AR signaling and favor ongoing neuroinflammatory signaling.
Conclusions
Our findings using highly selective A3AR agonists demonstrate that activation of the A3AR following TBI protects against tissue damage, brain infarct, neural inflammation and cognitive dysfunction. Given the good safety profiles of picladenosin and namodenosin, A3AR presents an exciting potential therapeutic target for prevention of permanent damage due to TBI.

Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12974-020-02009-7.

Additional file: Figure S1. \( \text{iso} \) and GAPDH Western blots. Uncropped images of Western blot images shown in Fig. 3a. Yellow box demarcates the cropped area. Figure S2. NF\( \beta \) and GAPDH Western blots. Uncropped images of Western blot images shown in Fig. 3b. Yellow box demarcates the cropped area. Figure S3. Phosphorylated and total p38 Western blots. Uncropped images of Western blot images shown in Fig. 3c. Yellow box demarcates the cropped area. Figure S4. Phosphorylated and total ERK Western blots. Uncropped images of Western blot images shown in Fig. 3d. Yellow box demarcates the cropped area. Figure S5. NLRP3, caspase 1 and GAPDH Western blots. Uncropped images of Western blot images shown in Fig. 4. Yellow box demarcates the cropped area. Blots shown in Fig. 3a and S1 were probed for NLRP3 and caspase 1 and share the same GAPDH image.

Abbreviations
A1AR: Adenosine receptor subtype 1; A2A AR: Adenosine receptor subtype 2A; A3AR: Adenosine receptor subtype 3; ASC: Apoptosis-associated speck-like protein containing a caspase activation and recruitment domain; CARD: Caspase activation and recruitment domain; CCI: Controlled cortical impact; CB-IB-MECA: 1-[2-Chloro-6-[[3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-[\( \beta \)-D-ribofuranuronamide; DAMPs: Danger associated molecular patterns; DMSO: Dimethyl sulfoxide; ERK: Extracellular signal-regulated kinase; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; GPCR: G protein-coupled receptor; IB-MECA: 1-Deoxy-1-[[3-iodophenyl][methyl]amino]-9H-purin-9-yl]-N-methyl-[\( \beta \)-D-ribofuranuronamide; NOD: Nucleotide-binding oligomerization domain; NFB: Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha; IL: Interleukin; MAPK: Mitogen-activated protein kinase; MRS5980: \( \left( 15 \text{S},2\text{R},3\text{S},4\text{R},5\text{S} \right) -4\text{-}(5\text{-chlorothiophen-2-yl)ethynyl}\text{-6-} \text{(methylamino)}\text{-9H-purin-9-yl)-2,3-dihydroxy-N-} \text{methylbicyclo}[3.1.0] \text{hexane-1-carboxamide; NF\( \beta \): Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha; NLRP3: NOD-like receptor pyrin domain-containing 3; NOD: Nucleotide-binding oligomerization domain-containing protein; NOPRT: Novel object-placement recognition test; P2X7: Adenosine triphosphate-gated P2X receptor cation channel subtype 7; TBI: Traumatic brain injury; v/v: Volume-to-volume; w/v: Weight-to-volume

Acknowledgements
Not applicable.

Authors’ contributions
SAF and DS conceived and designed the project and wrote the manuscript. SAF also performed closed weight drop TBI procedures, and collected and analyzed behavioral data. SC and EE performed and analyzed biochemical and histological data from CCI TBI studies and assisted in writing manuscript. MC performed histological analyses. MLN performed closed weight drop TBI procedures and behavioral studies. TMD analyzed data and assisted in writing the manuscript. The author(s) read and approved final manuscript.

Funding
Studies were supported by grants from the National Institute of Neurological Disorders and Stroke (NINDS), 1R01NS111120-01A1 (D. Salvemini and S. Farr).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Animal care and experiments were performed in agreement with Italian regulations on protection of animals used for experimental purposes (Ministerial Decree 16192), the Council Regulation (EC) (Official Journal of the European Union L 358/1 12/18/1986) and the National Institutes of Health NIH Guide for Care and Use of Laboratory Animals (USA). All procedures were approved by The University of Messina Review Board for the Care of Animals and Saint Louis University Institutional Animal Care and Use Committee.

Consent for publication
Not applicable.

Competing interests
Daniela Salvemini and Susan Farr have a patent (‘Treatment of Alzheimer’s Disease’ filed 02/25/2020, Serial No. PCT/US2020/019756) covering the intellectual property described in this manuscript. Daniela Salvemini is a founder of BiolIntervene, Inc. which has licensed related intellectual property from Saint Louis University and the National Institute of Health. All other authors declare no competing interests.

Author details
1Veterans Affairs Medical Center, 915 N Grand Blvd, St. Louis, MO 63106, USA.
2Department of Internal Medicine, Division of Geriatric Medicine, Saint Louis University School of Medicine, 1402 S. Grand Blvd, St. Louis, MO 63104, USA.
3Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 S. Grand Blvd, St. Louis, MO 63104, USA.
4Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, 1402 S. Grand Blvd, St. Louis, MO 63104, USA.
5Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, 98122 Messina, Italy.

Received: 24 July 2020 Accepted: 22 October 2020

Published online: 12 November 2020

References
1. Rachmany L, Tweedie D, Rubowitch V, Li Y, Holloway HW, Kim DS, Ratliff WA, Saykally JN, Citron BA, Hoffer BJ, et al. Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. Sci Rep. 2017;7:3755.
2. McKee CA, Lukens JR. Emerging Roles for the Immune System in Traumatic Brain Injury. Front Immunol. 2016;7:556.
3. Pop V, Badia J. A neurovascular perspective for long-term changes after brain trauma. Transl Stroke Res. 2011;2:33–45.
4. Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav Immun. 2012;26:1191–201.
5. Ramlakiansingh AF, Brooks DJ, Greenwood RJ, Bone SK, Turkheimer FE, Kinnunen KM, Gentleman S, Heckemann RA, Gunanayagam K, Gelosa G, Sharp DJ. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70:374–83.
6. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol. 2004;14:215–22.
7. Corps KN, Roth TL, McGavran DB. Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 2015;72:555–62.
8. Bell MJ, Kochanek PM, Carrillo JA, Mi Z, Schiding JK, Wisniewski SR, Clark RS, Marion CE, Marion DW, Jackson E. Interstitial adenosine, inosine, and hypoxanthine are increased after experimental traumatic brain injury in the rat. J Neurotrauma. 1998;15:163–70.
9. Robertson CL, Bell MJ, Kochanek PM, Adelson PD, Ruppel RA, Carrillo JA, Wisniewski SR, Mi Z, Janesko KL, Clark RS, et al. Increased adenosine in cerebrospinal fluid after severe traumatic brain injury in infants and children: association with severity of injury and excitotoxicity. Crit Care Med. 2001;29:2287–93.
10. Bell MJ, Robertson CS, Kochanek PM, Goodman JC, Gopinath SP, Carrillo JA, Clark RS, Marion DW, Mi Z, Jackson EK. Interstitial brain adenosine and
xanthine increase during jugular venous oxygen desaturations in humans after traumatic brain injury. Crit Care Med. 2001;29:399–404.
11. Boreu PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev. 2018;98:1591–625.
12. Varmo MR, Dixon CE, Jackson JK, Peters GW, Melick JA, Griffith RP, Vagni VA, Clark RS, Jenkins LW, Kocheanek PM. Administration of adenosine receptor agonists or antagonists after controlled cortical impact in mice: effects on function and histopathology. Brain Res. 2002;95/1:191–201.
13. Haselkorn ML, Shellington DK, Jackson EK, Vagni VA, Janosko-Feldman K, Dubey RK, Gillespie DG, Cheng D, Bell MJ, Jenkins LW, et al. Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice. J Neurotrauma. 2010;27:901–10.
14. Alvarez G, Munoz-Montano JR, Sarustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 1999;453:260–4.
15. Li W, Dai S, An J, Li P, Chen X, Zhao Y, Liu P, Wang H, Zhu P, et al. Genetic inactivation of adenosine A2A receptors attenuates acute traumatic brain injury in the mouse cortical impact model. Exp Neurol. 2009;215:69–76.
16. Lusardi TA, Lytle NK, Gebril HM, Boison D. Effects of Preinjury and Postinjury Exposure to Caffeine in a Rat Model of Traumatic Brain Injury. J Caffeine Adenosine Res. 2020;10:12–24.
17. Li W, Dai S, An J, Li P, Chen X, Xiong R, Liu P, Wang H, Zhao Y, Zhu M, et al. Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. Brain Res. 2014;151:119–207.
18. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol. 2009:295–58.
19. Boreu PA, Varani K, Vincenzi F, Baraldi PG, Tabrizi MA, Merighi S, Gessi S. The A3 adenosine receptor: history and perspectives. Pharmacol Rev. 2015;67:74–102.
20. Salvermii D, Jacobson KA. Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain. Expert Opin Ther Pat. 2017;27:947.
21. Effendi WN, Nagoa T, Kobayashi K, Ishimura Y. Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases. Cells. 2020;9:785.
22. Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rosenbaum M, Mader R, Adawi M, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol. 2008;35:41–6.
23. Stemmer SM, Benjamino D, Medalia G, Guranu NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpa Z, Farbstein M, Cohen S, et al. CF102 for the treatment of hepatocellular carcinoma: a phase II, open-label, dose-escalation study. Oncolst. 2013;18:25–6.
24. Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17:359–66.
25. Fredholm BB, Iizerman AP, Jacobson KA, Kotz KN, Linden J. International Union of Pharmacology. XXIV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–52.
26. Haesler D, Grassinger L, Fuchshuber F, Horlenbrecher UJ, Hofbitter R, Leisser I, Ginschele F, Shanab K, Spreitzer H, Gerdenitsch W, et al. Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor. Eur J Nucl Med Mol Imaging. 2015;42:928–36.
27. Von Lubitz DK, Simpson KL, Lin RC. Right thing at a wrong time? Adenosine A3 receptor activation as a brake on the microglial response after traumatic brain injury in mice. J Neurotrauma. 2010;27:901–10.
28. Jacobson KA, Merighi S, Varani K, Boreu PA, Baraldi S, Aghazadeh Tabrizi M, Romagnoli R, Baraldi PG, Clancetta A, Tosh DK, et al. A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. Med Res Rev. 2018;38:1031–72.
29. Tosh DK, Salmaso V, Rao H, Campbell R, Bitant A, Gao Z-G, Auchampach JA, Jacobson KA. Direct Comparison of (N-Methanocarba and Ribose-
traumatic brain injury: in vitro and in vivo effects. J Cereb Blood Flow Metab. 2002;22:444–52.

53. Ochoan A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Baeer F, Patoka R, De Valle L, et al. The A3 adenosine receptor agonist CGS512 inhibits the P53, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjunct-induced arthritis rats. Biochem Pharmacol. 2008;76:482–94.

54. Qiao Y, Wang P, Qi J, Zhang L, Gao C. TLR-induced NF-kappaB activation regulates NLRP3 expression in murine macrophages. FEBs Lett. 2012;586: 1022–6.

55. He Q, You H, Li XM, Liu TH, Wang P, Wang BE. HMGB1 promotes the synthesis of pro-l- Ibeta and pro-l-18 by activation of p38 MAPK and NF-kappaB through receptors for advanced glycation end-products in macrophages. Asian Pac J Cancer Prev. 2012;13:1365–70.

56. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183:787–91.

57. Ghonime MG, Shamaa OR, Das S, Eldomany RA, Fernandes-Alnemri T, Alnemri ES, Gavrilin MA, Wexers MD. Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function. J Immunol. 2014;192:3881–8.

58. Tsuchiya K, Hara H. The inflammasome and its regulation. Curr Rev Immunol. 2014;34:41–80.

59. Liu HO, Li W, Chen ZR, Hu YC, Zhang DD, Shen W, Zhou ML, Zhu L, Hang CH. Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. Neurochem Res. 2013;38:2072–83.

60. Ismail S, Nassooh S, Ishrat T. MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury. J Neurotrauma. 2018;35:1294–303.

61. Kowar R, Roffe A, Di I, Xu H, He L, Jiang Y, Zhang S, Sun D. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation. 2019;16:81.

62. Ferrer I, Sánchez-Sánchez A, Chillón JA, Sánchez-Madrid F, Abelló J, et al. Lack of the Nlrp3 Inflammasome Improves Mice against Traumatic Brain Injury. J Neurotrauma. 2018;35:1294–402.

63.创办 D, Kuru Bektaşğ F, Farr P. Adenosine A3 receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. Pain. 2014;155:2560–7.

64. Garcia JM, Stillings SA, Leclerc JL, Phillips H, Edwards NJ, Robicsek SA, Hoh BL, Blackman S, Dore S. Role of Interleukin-10 in Acute Brain Injuries. Front Neurol. 2017;8:244.

65. Antonicoli L, Pacher P, Vozi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2016;22:213–27.

66. McKee AC, Daneshvar DH. The neuropathology of traumatic brain injury. Handb Clin Neurol. 2015;127:45–66.

67. Advocaat D, Van den B, Gürer B. Neuroprotective effects of mildronate in a mouse model for juvenile, lateral fluid percussion brain injury reveals sex-dependent differences in neuroinflammation and functional recovery. J Neurotrauma. 2020;37:635–46.

68. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in rats. Purinergic Signal. 2017;13:3529–44.

69. Tosh DK, Cuzzocrea S, Jacobson KA, Salvemini D. Chemotherapy-induced inflammation: a potential role for neuronal glutaminase. J Neurochem. 2013;125:897–908.

70. Jones A, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, Salvemini D. A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. Pain. 2014;155:2560–7.

71. Garcia JM, Stillings SA, Leclerc JL, Phillips H, Edwards NJ, Robicsek SA, Hoh BL, Blackman S, Dore S. Role of Interleukin-10 in Acute Brain Injuries. Front Neurol. 2017;8:244.

72. Advocaat D, Van den B, Gürer B. Neuroprotective effects of mildronate in a mouse model for juvenile, lateral fluid percussion brain injury reveals sex-dependent differences in neuroinflammation and functional recovery. J Neurotrauma. 2020;37:635–46.

73. Antonicoli L, Pacher P, Vozi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2016;22:213–27.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.